Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenosine deaminase co-immunization reverses age-associated immunosenescence by restoring germinal center T follicular helper cell function.

bioRxiv : the preprint server for biology·2026
Same author

Mechanistic analysis of MLKL-driven cell survival.

Cell death discovery·2026
Same author

Early immune events during SARS-CoV-2 infection impact memory T and B cell responses.

Communications biology·2026
Same author

ACSS2 Suppresses Ferroptosis to Drive Breast Cancer Brain Metastasis.

Cancer research·2026
Same author

Sugar Storm: O-GlcNAc signaling amid the clouds of cancer complexity.

Glycobiology·2026
Same author

Generation and characterization of a novel MHC-II tetramer for tracking and characterization of toxin B-specific CD4<sup>+</sup> T cell responses.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 9, 2026

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

Adenosine as a metabolic checkpoint in CD8+ T cell dysfunction.

Arden O Edgerton1, Mauricio J Reginato2, Michele A Kutzler3

  • 1Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.

Trends in Immunology
|July 7, 2026
PubMed
Summary

Adenosine signaling drives CD8+ T cell dysfunction in cancer and chronic infections. Targeting the adenosine-adenosine deaminase-1 axis may restore immune function against these diseases.

Keywords:
ADA-1CD8+ T cellsT cell dysfunctionadenosinechronic infectiontumor microenvironment

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Related Experiment Videos

Last Updated: Jul 9, 2026

Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Area of Science:

  • Immunology
  • Cancer Biology
  • Virology

Background:

  • CD8+ T cell dysfunction impairs immune control in cancer and chronic viral infections.
  • This dysfunction arises from distinct diseases but shares common regulatory pathways.
  • Adenosine (ADO) is an immunosuppressive metabolite that acts as a metabolic checkpoint in immune responses.

Purpose of the Study:

  • To review how the adenosine-adenosine deaminase-1 axis influences CD8+ T cell dysfunction.
  • To explore ADO signaling's role in stabilizing dysfunctional T cell states across diseases.
  • To discuss the potential of targeting this axis for immune restoration.

Main Methods:

  • Literature review focusing on adenosine metabolism and T cell function.
  • Analysis of studies investigating ADO signaling in tumor microenvironments and HIV infection.
  • Examination of regulatory pathways linking ADO to T cell dysfunction.

Main Results:

  • Dysregulated ADO signaling reinforces immune checkpoint pathways in both cancer and HIV.
  • The ADO-adenosine deaminase-1 axis contributes to sustained CD8+ T cell dysfunction.
  • ADO acts as a context-integrating checkpoint regulating immune responses.

Conclusions:

  • The ADO-adenosine deaminase-1 axis is a key driver of CD8+ T cell dysfunction.
  • Targeting this axis presents a potential therapeutic strategy for immune restoration in various diseases.
  • Understanding ADO's role is crucial for developing novel immunotherapies.